Search

* ViaCell will begin to enroll patients in a Phase I/II clinical trial of CB001, a highly purified population of stem cells that has been isolated from umbilical cord blood [...]

Abgenix Inc. and Immunex Corp. said they will initiate a Phase II tolerability and efficacy trial of the monoclonal antibody ABX-EGF as a monotherapy against kidney cancer. The 80-patient North [...]

Lolla Pharmaceutical Co. is back on track with Its lupus drug UP 394, armed with stronger data and prepared to begin a Phase III trial in the second half of [...]

Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: December 1999 Company [*] Product Description (Symbol) CANCER ImClone Systems C225 Monoclonal antibody that Inc. (IMCL) and targets and inhibits the epi- [...]

Amgen Inc.'s therapy for Parkinson's disease failed to meet its primary endpoint in a Phase II study. The company's glial cell line-derived neurotrophic factor, also called CDNF, did not show [...]

* EntreMed has initiated the University of California San Francisco (UCSF) as a second location for a Phase II clinical trial of its angiogenesis inhibitor, Endostatin, for neuroendocrine tumors. UCSF [...]

Oxford BioMedica plc, of Oxford, UK, said the independent data safety monitoring board for the Phase III study of its gene therapy, TroVax, in renal cancer has concluded that the [...]

Myogen Inc. hoped to complete enrollment in its Phase III trials of ambrisentan in pulmonary arterial hypertension by mid-year, but the company reported a six-month delay in enrollment due to [...]

La Jolla Pharmaceutical Co. is padding its bank account, courtesy of a $17.2 million public offering. The San Diego-based company on Jan. 28 agreed to sell 12.25 million common shares [...]

Not long after gaining a public listing, CepTor Corp. added capital through a $12 million stock-and-warrant sale and plans to use the proceeds for its lead product, Myodur. The drug [...]

La Jolla Pharmaceutical Co. received an approvable letter for its lupus drug candidate Riquent that requires the completion of another clinical study for final approval. That study could take up [...]

Agendia BV (Amsterdam, the Netherlands), a recently formed start-up, is planning three large, scale clinical trials of a genomics-based method for predicting the chance of primary breast cancers to recur [...]

* NeuroSearch A/S, of Ballerup, Denmark, said it obtained promising preclinical data for the anticancer compound Endovion (NS3728), and it is now considering a Phase II trial and is looking [...]

* Genmab A/S, of Copenhagen, Denmark, filed a clinical trial application in Europe to start an open-label Phase I/II clinical study of HuMax-EGFr for head and neck cancer. The company [...]

* CardioTech International (Woburn, MassachuSetts) completed preparations for a human clinical trial for its CardioPass coronary artery bypass graft. The trial is scheduled to be initially conducted in Brazil, and [...]

* Cardiome Pharma (Vancouver, British Columbia) laid out a strategy to begin a Phase III program for RSD1235, its homegrown anti-arrhythmic product. Scheduled to begin in the second half of [...]

* Alizyme plc, of Cambridge, UK, said it completed recruitment of 170 patients in a Phase llb study of renzapride in the treatment of alternating, or mixed-symptom, irritable bowel syndrome [...]

* SkyePharma plc, of London, said its Biosphere sustained-release injectable technology has been successful in delivering a protein drug over an extended period of time. The company said that in [...]

* Phytopharm plc, of Godmanchester, UK, said it started the second Phase I study of P58, a treatment for age-related cognitive dysfunction. The study will enroll 30 healthy subjects aged [...]

* Scios has begun enrollment in a Phase IIa clinical trial evaluating SCIO-469, its novel oral p38 kinase inhibitor for the treatment of rheumatoid [...]

* Hybridon has initiated a Phase I/II clinical trial to study the combination of GEM(R)231, its second-generation antisense drug candidate, and the marketed antitumor chemotherapy agent, irinotecan (CPT-11; Camptosar) for [...]

* Alexion Pharmaceuticals has completed enrollment in its first Phase II trial in patients suffering from a severe form of kidney disease known as membranous nephritis, with its anti-inflammatory C5 [...]

* Achillion Pharmaceuticals has commenced a Phase II clinical study with ACH-126,443 (beta-L-Fd4C) in patients with chronic hepatitis B [...]

* Repligen Corp. has initiated its Phase III clinical trial program for secretin in pediatric autism. Based on feedback from the Food and Drug Administration, the Company intends to conduct [...]

A pilot study recently begun in San Francisco could lead to a large-scale research trial involving HIV patients that would help answer the question of when to start treatment with [...]